The company reported strong third-quarter results with double-digit sales growth of 12.6%, reaching $1.55 billion. This performance was driven by its comprehensive portfolio across multiple therapeutic areas, including aortic, pulmonic, mitral, and tricuspid treatments, as well as its established global presence. Investors have been rewarded, with the stock delivering a 20% return over the past year, indicating positive market performance and investor satisfaction with the company's recent financial results.